We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Retrospective Analysis of Definitive Chemoradiotherapy With FOLFOX in Patients With Esophageal Cancer Intolerant to Cisplatin.
- Authors
MAYU YADA; SHUN YAMAMOTO; YOSHITAKA HONMA; HIDEKAZU HIRANO; NATSUKO OKITA; HIROKAZU SHOJI; SATORU IWASA; ATSUO TAKASHIMA; AKIHITO NAGAHARA; KEN KATO
- Abstract
Background/Aim: Definitive chemoradiotherapy with cisplatin (CDDP) plus 5-fluorouracil is the standard treatment for locally advanced esophageal squamous cell carcinoma (LA-ESCC); however, CDDP is unsuitable for patients with cardiac and/or renal dysfunction. Based on the results of the PRODIGE5/ACCORD17 trial, 5-fluorouracil and leucovorin with oxaliplatin plus radiotherapy (FOLFOX-RT) has been recognized as a treatment option. However, the efficacy and safety of FOLFOX-RT is still unclear in Japan. Patients and Methods: Medical records were reviewed for patients with LA-ESCC who received FOLFOX-RT between April 2019 and July 2021 at our institution. We evaluated complete response rate, progression-free survival (PFS), overall survival (OS), and adverse events. Results: Fifteen patients were analyzed and median age was 72.5 years (range=51-83 years). All patients completed three courses of FOLFOX and the planned radiotherapy. The complete response rate was 40.0%. With a median follow-up of 10.6 months, the 6-month PFS rate was 63.0% (95%CI=32.3-82.8%), and the 6-month OS rate was 85.7% (95%CI=53.9-96.2%). Common adverse events were esophagitis (80.0%), leukopenia (53.3%), fatigue (53.3%), and neutropenia (46.7%). Only one patient had grade 4 esophageal perforation. Conclusion: FOLFOX-RT for LA-ESCC was well tolerated and could be a treatment option for CDDP-intolerant patients.
- Subjects
TREATMENT of esophageal cancer; RETROSPECTIVE studies; CHEMORADIOTHERAPY; CISPLATIN; SQUAMOUS cell carcinoma
- Publication
In Vivo, 2024, Vol 38, Issue 2, p761
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.13499